|
Accession Number
|
PB2007-102051
|
|
Title
|
Modeling the Cost Effectiveness of Etanercept, Adalimumab and Anakinra Compared to Infliximab in the Treatment of Patients with Rheumatoid Arthritis in the Medicare Program.
|
|
Publication Date
|
Oct 2006
|
|
Media Count
|
74p
|
|
Personal Author
|
N/A
|
|
Abstract
|
A cost effectiveness analysis of infliximab versus etanercept, adalimumab and anakinra has been performed from the viewpoint of Medicare as part of the Medicare Replacement Drug Demonstration Program. The model draws on synthesis of randomized controlled ...
|
|
Keywords
|
Adalimumab
Anakinra
Benefits
Biologics
Clinical trials
Cost effectiveness
Costs
Etanercept
Infliximab
Medicare
Medicare Replacement Drug Demonstration Program
Rheumatoid arthritis
|
|
|
Source Agency
|
National Center for Health Services Research
|
|
NTIS Subject Category
|
57E - Clinical Medicine
57Q - Pharmacology & Pharmacological Chemistry
44H - Health Care Technology
44Q - Health Related Costs
|
|
Corporate Author
|
Agency for Healthcare Research and Quality, Rockville, MD.
|
|
Document Type
|
Technical report
|
|
Title Note
|
N/A
|
|
NTIS Issue Number
|
0704
|
|
Contract Number
|
N/A
|
